{"date":"2025-12-03","count":12,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-1795-2025-12-03-1936-mkwpl7","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2025-12-03","time":"19:36:33","subject":"本公司透過子公司投資並取得NAGH全數股權業已於114/12/3完成交易 (補充114/09/24公告)","clause":"第20款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：美時（1795），2025-12-03 19:36，「本公司透過子公司投資並取得NAGH全數股權業已於114/12/3完成交易 (補充114/09/24公告)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6976-2025-12-03-1917-1srz6xi","company_id":"6976","company":"育世博-KY","market":"興櫃","industry":"生技醫療","date":"2025-12-03","time":"19:17:35","subject":"代重要子公司Acepodia Biotech,Inc公告細胞新藥ACE1831用於第四型免疫球蛋白G相關疾病之Ib/IIa期臨床試驗獲得中國NMPA核准執行","clause":"第44款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：育世博-KY（6976），2025-12-03 19:17，「代重要子公司Acepodia Biotech,Inc公告細胞新藥ACE1831用於第四型免疫球蛋白G相關疾病之Ib/II」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2025-12-03-1802-jlgntf","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2025-12-03","time":"18:02:36","subject":"公告本公司與Rxilient Medical Pte. Ltd.簽署眼部術後炎症和疼痛治療新藥APP13007於東協市場之獨家授權合約","clause":"第10款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2025-12-03 18:02，「公告本公司與Rxilient Medical Pte. Ltd.簽署眼部術後炎症和疼痛治療新藥APP13007於東協市場」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4114-2025-12-03-1801-zjut0s","company_id":"4114","company":"健喬","market":"上櫃","industry":"生技醫療","date":"2025-12-03","time":"18:01:49","subject":"公告本公司向關係人租賃取得不動產使用權資產(租賃面積調整)","clause":"第20款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：健喬（4114），2025-12-03 18:01，「公告本公司向關係人租賃取得不動產使用權資產(租賃面積調整)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2025-12-03-1632-1oak65c","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-03","time":"16:32:24","subject":"公告本公司114年現金增資認股基準日暨相關事宜(補充代收股款及存儲專戶行庫)","clause":"第9款","fact_date":"2025-12-01","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2025-12-03 16:32，「公告本公司114年現金增資認股基準日暨相關事宜(補充代收股款及存儲專戶行庫)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2025-12-03-1610-1iix6qa","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2025-12-03","time":"16:10:06","subject":"公告本公司114年現金增資發行新股認股基準日等相關事宜(補充公告發行價格、代收股款及存儲價款專戶機構)","clause":"第11款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2025-12-03 16:10，「公告本公司114年現金增資發行新股認股基準日等相關事宜(補充公告發行價格、代收股款及存儲價款專戶機構)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2025-12-03-1558-1539i68","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2025-12-03","time":"15:58:01","subject":"本公司受邀參加台灣證券交易所股份有限公司舉辦之法人說明書","clause":"第12款","fact_date":"2025-12-04","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2025-12-03 15:58，「本公司受邀參加台灣證券交易所股份有限公司舉辦之法人說明書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2025-12-03-1549-suok8v","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2025-12-03","time":"15:49:29","subject":"公告本公司董事會決議取消召開114年第二次股東臨時會","clause":"第44款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2025-12-03 15:49，「公告本公司董事會決議取消召開114年第二次股東臨時會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2025-12-03-1512-1xeooua","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-12-03","time":"15:12:05","subject":"公告本公司股票初次上櫃前現金增資認股繳款期間暨暫定承銷價相關事宜","clause":"第44款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-12-03 15:12，「公告本公司股票初次上櫃前現金增資認股繳款期間暨暫定承銷價相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2025-12-03-1510-1bnswtb","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-12-03","time":"15:10:51","subject":"公告本公司初次上櫃現金增資委託代收及存儲價款機構","clause":"第44款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-12-03 15:10，「公告本公司初次上櫃現金增資委託代收及存儲價款機構」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2025-12-03-1510-qkrt5g","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-12-03","time":"15:10:16","subject":"公告本公司股務代理機構名稱、辦公處所及聯絡電話","clause":"第44款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-12-03 15:10，「公告本公司股務代理機構名稱、辦公處所及聯絡電話」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4157-2025-12-03-0658-1p0jw6q","company_id":"4157","company":"太景*-KY","market":"上櫃","industry":"生技醫療","date":"2025-12-03","time":"06:58:43","subject":"公告正式接獲合作夥伴健康元藥業集團通知抗流感病毒新藥Pixavir marboxil小兒劑型於中國大陸之第一期臨床試驗結果","clause":"第10款","fact_date":"2025-12-03","cite_as":"公開資訊觀測站重大訊息：太景*-KY（4157），2025-12-03 06:58，「公告正式接獲合作夥伴健康元藥業集團通知抗流感病毒新藥Pixavir marboxil小兒劑型於中國大陸之第一期臨床試驗結」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}